Table 2

Detailed characteristics of SLE patients included in this study

No. Patients

Stage

Treatments

Doses (mg/d)

SLEDAI score

Clinical Features


1

inactive

-

-

4

PI

2

inactive

PRD, AZT

5, 50

0

-

3

inactive

PRD, AZT

35, 12.5

4

RA, MU

4

inactive

PRD, AZT

5, 25

1

FE

5

inactive

PRD

N/A

5

RA, MU, FE

6

inactive

PRD

2.5

0

-

7

inactive

PRD, CPM

10, N/A

4

PU

8

inactive

PRD

5

4

AR

9

inactive

-

-

4

PU

10

inactive

PRD

5

0

-

11

inactive

PRD, AZT

10, 50

4

PU

12

inactive

PRD, CPM

7.5, 25

0

-

13

inactive

PRD, CPM

10, 25

4

PU

14

inactive

PRD

10

2

MU

15

inactive

PRD, AZT

7.5, 100

5

PU, LP

16

inactive

-

-

0

-

17

active

PRD, AZT

5, 100

8

HE, PU

18

active

-

-

8

HE, PU

19

active

PRD, MMF

2.5, 2,000

8

HE, PU

20

active

PRD

15

30

SZ, UC, HE, PU, PI, PE, LC, IDB

21

active

PRD, AZT

5, 25

11

MY, HE, PL, LP

22

active

PRD

5

8

AR, PU

23

active

PRD, AZT

30, 50

29

VA, AR, HE, PU, PI, RA, MU, LP

24

active

PRD

30

11

PU, AL, PL, FE, TC, LP

25

active

PRD, AZT

5, 50

8

VA

26

active

PRD, MMF

5, 500

13

HE, PU, AL, MU, LP

27

active

PRD

20

12

HE, PU, PI

28

active

PRD, AZT

20, 25

16

VA, PU, MU, LC

29

active

PRD

15

6

PU, LC


AL, alopecia; AR, arthritis; AZT, azathioprine; CPM, cyclophosphamide; FE, fever; HE, hematuria; IDB, Increased DNA binding; LC, low complement; LP, leucopenia; MMF, mycophenolate mofetil; MU, mucosal ulcers; MY, myositis; N/A, data not available; PE, pericarditis; PI, pyuria; PL, pleurisy; PRD, prednisolone; PU, proteinuria; RA, rash; SZ, seizure; TC, thrombocytopenia; UC, urinary casts; VA, vasculitis.

Puwipirom et al. Arthritis Research & Therapy 2010 12:R215   doi:10.1186/ar3194

Open Data